Immunic Inc IMUX

NAS: IMUX | ISIN: US4525EP1011 17/05/2024

1,245 USD (-0,40%)

(-0,40%) 17/05/2024

Grafiek Immunic Inc

Grafiek Immunic Inc

1 dag1d -0,40%
1 week1w -0,80%
1 maand1m 1,22%
3 maanden3m -8,12%
6 maanden6m 12,16%
1 jaar1j -36,80%
5 jaar5j -87,11%

Immunic Inc in het nieuws

Toon enkel gratis nieuws

8 mei 2024 · Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update · Persbericht

6 mei 2024 · Immunic to Participate in Investor and Scientific Conferences in May · Persbericht

1 mei 2024 · Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update · Persbericht

30 april 2024 · Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation · Persbericht

4 april 2024 · Immunic to Host MS R&D Day and Participate in Investor Conferences in April · Persbericht

20 maart 2024 · Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States · Persbericht

7 maart 2024 · Immunic to Participate in Investor and Scientific Conferences in March · Persbericht

29 februari 2024 · Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024 · Persbericht

22 februari 2024 · Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update · Persbericht

15 februari 2024 · Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update · Persbericht

Profiel Immunic Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

CEO: Daniel Vitt

Werknemers: 58

Aandelen Immunic Inc

Beurswaarde: 112,15 miljoen USD

Effecten: 90,08 miljoen

Beta: 2,09

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe